logo
Viral carrot ribbon salad changing how people consume vegetables: 'Eat our skincare'

Viral carrot ribbon salad changing how people consume vegetables: 'Eat our skincare'

Fox News6 days ago

There's a new and viral way to get your vegetables.
Chef and content creator Cassie Yeung recently posted an online video of her carrot ribbon salad.
In the video, she strips a whole load of carrots into long, thin ribbons to make a salad.
Yeung said she was going out of town and needed to use up her carrots so they didn't go to waste.
She opted for the shredding method to make them easier to eat.
"Not just straight like this," she said in the video, referring to the raw carrots in front of her.
"When I make a carrot ribbon salad, I can quite literally eat all of these carrots."
Yeung then proceeded to add green onions, grated garlic, sesame seeds, sesame oil, soy sauce, rice wine vinegar and chili crisp oil before mixing all of it with her hands in a large bowl. (See the video at the top of this article, showing an attempt at this recipe.)
People who tried it sounded off in the comments, claiming they loved it and that it inspired them to eat their vegetables.
Many were also inspired by Yeung's claim that carrots are good for hormones and that this is a way to "eat our skincare."
Fox News Digital reached out to Yeung for additional comment.
Studies have shown that eating carrots does boost skin health.
Eating baby carrots at least three times a week increased skin carotenoids, which are not only associated with improved skin health, but also lower risk of chronic diseases like heart disease and certain cancers, according to a 2024 study by Samford University.
"The nutrients found in carrots may also help to improve skin health by hydrating, protecting against UV rays and aiding in collagen production for elasticity and anti-aging effects," New Jersey-based dietitian Erin Palinski-Wade told Fox News Digital.
While there is not as much scientific evidence that carrots are good for hormones, they are high in fiber, which can promote good gut health.
For more Lifestyle articles, visit foxnews.com/lifestyle
The link between good gut health and hormone balance has been studied.
One study published in the journal Frontiers in Microbiology links the gut microbiome and the possible reduction of sex hormone-related diseases.
To incorporate more carrots into your diet, Palinski-Wade said there are plenty of ways to do so beyond the carrot ribbon salad.
Carrots can be eaten "raw as a snack with dips, grated into salads, blended into smoothies, roasted, added to casseroles, soups or stews, and even used in sweet or spicy glazes for variety and flavor," she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

U.S. Supreme Court orders review over religious challenge to New York abortion law
U.S. Supreme Court orders review over religious challenge to New York abortion law

Yahoo

time42 minutes ago

  • Yahoo

U.S. Supreme Court orders review over religious challenge to New York abortion law

The U.S. Supreme Court on Monday ordered a lower court in New York to reevaluate whether some religious organizations should be excluded from a state mandate that requires employers to provide employee health care plans that include abortion coverage. The ruling from the high court said the case, Diocese of Albany v. Harris, should be sent back to New York courts to be reviewed again in light of an earlier unanimous Wisconsin case related to the Catholic Church groups being denied state tax exemptions. The justices pointed to the Wisconsin case because the New York case poses similar issues about states exempting religious employers and faith-based groups, The Associated Press reported. The New York case stems from a 2017 state mandate that requires health insurance plans provided by employers to include abortion coverage for situations that include rape and incest. The state mandate includes a religious exemption for institutions, but not for religious-affiliated groups. It was challenged by Catholic and Anglican nuns, Catholic dioceses, Christian churches and other faith organizations. They argued the religious exemption is so narrow that it violates the freedom of religion protected under the First Amendment. The most recent order from the Supreme Court is the second time the case has reached the justices after being litigated for years. After the state adopted the mandate in 2017, religious groups challenged it in state court. The appeals court upheld the regulation and the state refused to exempt religious organizations. In 2021, the religious groups appealed the state's ruling to the U.S. Supreme Court. Justices asked New York to reconsider based on its ruling in another case involving religion, Fulton v. Philadelphia. State courts found the Fulton decision was inapplicable to the situation, prompting the groups to bring it to the Supreme Court again. The religious liberty law firm Becket noted in a release that New York's exemption doesn't currently apply to some organizations, including the Carmelite Sisters for the Aged and Infirm and the Teresian Nursing Home because they 'serve the elderly and dying regardless of religious affiliation.' 'New York wants to browbeat nuns into paying for abortions for the great crime of serving all those in need,' Becket Vice President and senior counsel Eric Baxter said in a statement.' Following the Supreme Court's Monday order, the case is headed back to the New York Court of Appeals.

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Yahoo

time2 hours ago

  • Yahoo

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent

Yahoo

time2 hours ago

  • Yahoo

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store